Table 3. Patient characteristics and laboratory results in the six patients with vaccine infection in the Gothenburg area, Sweden, December 2017–January 2018 (n = 6).

Patient	Age group (years)	Days from onset of rash to sampling	Symptoms	IgM	IgG (mIU/mL)	Ct value NP	Ct value urine	Ct value blood	IgM-FU	IgG-FU (mIU/mL)
29	11–20	0	R F K C Z	Neg	Neg	32	33	38	Equivocal	2,750
30	31–40	0	R F K	Neg	Equivocal	32	30	40	Pos	4,027
31	41–50	1	R F C	Pos	Neg	19	31	38	ND	ND
32	51–60	0	R F	Neg	Neg	32	29	Neg	Neg	1,345
33	41–50	1	R F K C Z	Neg	Neg	Neg	ND	Neg	Neg	1,582
34	51–60	1	R F	Equivocal	Neg	26	Neg	39	ND	ND

C: cough; Ct: cycle threshold; F: fever; FU: follow-up visit; K: conjunctivitis; ND: not done; Neg: negative; NP: nasopharyngeal secrete; Pos: positive; R: rash; Z: coryza.